Nabi names new senior vice president, global sales and marketing

Nabi Biopharmaceuticals named Le Roux Jooste senior vice president, global sales and marketing, a new position. Jooste joins from Cephalon, a biotechnology company, where he was vice president worldwide product planning.

This newly created position recognizes the increasing pace of Nabi Biopharmaceuticals' strategic transformation and its increasing commitment to developing and commercializing products that address global, unmet medical needs. Mr. Jooste will be responsible for advancing the company's commercial presence in Europe and in other important markets around the world. He will direct the launches of Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], PhosLo(R) (Calcium Acetate) and StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine] in Europe; build sales, marketing and reimbursement initiatives for the company's currently marketed products; and lead the planning for the launch of StaphVAX in the United States.

"Le Roux is known as a leader with a proven track record in marketing and sales performance, extensive product launch experience, thorough knowledge and understanding of key international markets, as well as expertise in the development of new products and new businesses on a global scale. He brings important experience and knowledge in establishing and growing some of the industry's most successful brands. We are extremely pleased to have someone of Mr. Jooste's caliber lead our global commercialization efforts and work with our team as we advance Nabi Biopharmaceuticals to the next level of achievement," said Thomas McLain, Nabi Biopharmaceuticals' chairman, chief executive and president.

You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.